Cardiovascular Outcomes of Differentiated Thyroid Cancer Patients on Long Term TSH Suppression: A Systematic Review and Meta-Analysis
Horm Metab Res 2023; 55: 379-387 DOI: 10.1055/a-2084-3408We performed a systematic review and meta-analysis of the literature regarding
cardiovascular outcomes of differentiated thyroid cancer (DTC) patients who are
on long term thyroid stimulating hormone suppression. Searches were carried out
using Prisma guidelines in Medline, Embase, CENTRAL, CINAHL and Scopus
databases. Eligible papers were those which investigated discrete cardiovascular
clinical outcomes in TSH suppressed patients and meta-analysis of selected
studies was performed using Revman 5.4.1. We found a total of 195 879 DTC
patients with median length to follow up of 8.6 years (range 5–18.8
years). Analysis showed DTC patients to be at higher risk of atrial fibrillation
(HR 1.58, 95% CI 1.40, 1.77), stroke (HR 1.14, 95% CI 1.09,
1.20) and all-cause mortality (HR 2.04, 95% CI 1.02, 4.07). However,
there was no difference in risk of heart failure, ischemic heart disease or
cardiovascular mortality. These findings suggest that degree of TSH suppression
must be titrated to accommodate risk of cancer recurrence and cardiovascular
morbidity. [...] Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart,
GermanyArticle in Thieme eJournals: Table of contents | Abstract | Full text
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Yu, Jerry Kaur, Rajneesh Ayeni, Femi Emmanuel Eslick, Guy D. Edirimanne, Senarath Tags: Original Article: Endocrine Care Source Type: research
More News: Atrial Fibrillation | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Databases & Libraries | Endocrinology | Heart | Heart Disease | Heart Failure | Hormones | Ischemic Stroke | Stroke | Study | Thyroid | Thyroid Cancer